Colorectal | Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal Cancer

2:13:02
 
Share
 

Manage episode 234152847 series 1464173
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.

A roundtable discussion featuring perspectives from Drs Tanios Bekaii-Saab and Alan P Venook on emerging research and cases from their practices.

  • Introduction — Indications for and Practical Implementation of Biomarker Analysis for Patients with Metastatic Colorectal Cancer (mCRC)
    • Biomarker assessment for patients with mCRC (0:00)
    • Perspectives on genomic testing platforms used to perform biomarker analysis for mCRC (3:16)
    • Role of rebiopsy and repeat biomarker assessment for patients with progressive mCRC (7:11)
  • Biology of mCRC and Role of Tumor Sidedness in First- and Later-Line Decision-Making
    • Implications of RAS testing for selection of therapy (10:22)
    • Tumor sidedness and therapeutic decision-making (13:55)
    • Similarities and differences in the design and primary endpoints of the Phase III CALGB-80405 and FIRE-3 trials evaluating first-line chemotherapy in combination with cetuximab and/or bevacizumab for KRAS wild-type mCRC (18:12)
    • Prognostic and predictive relevance of primary tumor sidedness in patients with RAS wild-type mCRC on the CALGB-80405 and FIRE-3 trials (22:11)
    • Efficacy of EGFR inhibitor- versus bevacizumab-based treatments for left- versus right-sided RAS wild-type mCRC (23:28)
    • Choosing between EGFR inhibitor- and bevacizumab-based treatments as first- and second-line therapy for patients with symptomatic left-sided RAS wild-type mCRC (31:39)
    • Case (Dr Venook): A woman in her thirties with left-sided RAS wild-type mCRC receives first-line FOLFOXIRI (40:14)
    • Therapeutic options for younger patients with left-sided RAS wild-type mCRC and disease progression on first-line FOLFOXIRI (43:58)
    • Case (Dr Bekaii-Saab): A man in his sixties with left-sided RAS wild-type mCRC and disease progression after 2 years of first-line “stop-and-go” FOLFIRI/bevacizumab receives FOLFIRI/panitumumab (45:56)
    • Activity of cetuximab versus panitumumab and practical considerations for use (49:37)
    • Clinical experience with and management of EGFR inhibitor-associated dermatologic toxicities (51:45)
    • Second opinion: Second-line therapy options for patients with left-sided RAS wild-type mCRC and disease progression on first-line FOLFIRI/bevacizumab (55:48)
    • Faculty perspectives on therapeutic algorithms for first- through later-line therapy for left- versus right-sided RAS wild-type mCRC (1:00:43)
  • Current and Future Treatment Options for Patients with BRAF Mutations
    • Efficacy of EGFR inhibition in patients with mCRC and atypical (non-V600E) BRAF mutations (1:08:18)
    • Clinical presentation of and prognosis for patients with mCRC and a BRAF V600E tumor mutation (1:12:22)
    • Activity and tolerability of EGFR/MEK/BRAF-inhibitor combinations in patients with mCRC and a BRAF V600E tumor mutation (1:13:59)
    • Importance of BRAF testing in mCRC; strategies for first-line therapy and beyond (1:16:13)
    • Improved tolerability with triplet EGFR/MEK/BRAF-inhibitor combinations in comparison to anti-EGFR monotherapy or doublet combinations (1:19:54)
    • Case (Dr Venook): A woman in her forties with mCRC, a BRAF V600E tumor mutation and rapid disease progression on first-line FOLFOXIRI/bevacizumab attains long-term disease stabilization with encorafenib/binimetinib/panitumumab (1:22:13)
    • Case (Dr Bekaii-Saab): A man in his fifties with mCRC and a BRAF V600E tumor mutation receives second-line encorafenib/binimetinib/cetuximab on a clinical trial (1:23:27)
  • Optimal Management of Microsatellite Instability (MSI)-High or DNA Mismatch Repair-Deficient mCRC
    • Assessment of MSI status and tumor mutation burden as predictors of response to immune checkpoint blockade (1:26:47)
    • Sequencing of anti-PD-1/PD-L1 checkpoint inhibitors for MSI-high mCRC (1:33:19)
    • Neoadjuvant ipilimumab with nivolumab for early-stage colon cancer (1:36:39)
    • Activity and tolerability of immune checkpoint inhibitors alone and in combination in patients with MSI-high mCRC (1:37:34)
    • Case (Dr Bekaii-Saab): A woman in her fifties with MSI-high, right-sided mCRC and a RAS mutation receives second-line pembrolizumab (1:42:11)
    • Case (Dr Venook): A woman in her forties with Stage III CRC initially treated with adjuvant FOLFOX experiences disease progression and receives an assessment of MSI-high disease (1:46:37)
    • Perspective on pseudoprogression in patients undergoing immune checkpoint inhibitor therapy (1:48:50)
  • HER2 Positivity and Other Potential Biomarkers
    • Biology and epidemiology of mCRC with HER2 amplification/mutation (1:51:16)
    • Activity of and duration of response to dual HER2-targeted therapy in patients with mCRC and HER2 amplification/mutation (1:54:09)
    • Therapeutic options for patients with mCRC and HER2 amplification/mutation (1:55:45)
    • Case (Dr Venook): A man in his fifties with left-sided, RAS wild-type mCRC and HER2 amplification/mutation receives fourth-line trastuzumab/pertuzumab (2:00:13)
    • Case (Dr Bekaii-Saab): A woman in her sixties with left-sided, RAS wild-type mCRC and HER2 amplification/mutation receives third-line trastuzumab/tucatinib on a clinical trial (2:01:57)
    • Activity of tucatinib in patients with mCRC and HER2 amplification/mutation (2:04:40)
    • Optimizing the risk-benefit ratios of systemic therapy options for patients with mCRC (2:07:36)
    • Modulation of the gut microbiome to enhance response to anti-PD-1 immunotherapy; effects of antibiotics on response to immune checkpoint inhibitors (2:11:12)

Select publications

2175 episodes available. A new episode about every 2 days averaging 75 mins duration .